Lynn Tetrault's departure as Chair of the Board of Neogenomics Inc was reported, effective January 4, 2027; the filing names no successor. As of November 6, 2026, Neogenomics Inc has reported 3 leadership change filings to the SEC under Item 5.02 of Form 8-K, from June 25, 2026 to October 5, 2026, naming 1 appointment and 1 departure (Form 8-K, October 5, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Neogenomics Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · In / out: Out · Person: Lynn Tetrault · Role: Chair of the Board · Effective: 2027-01-04 · 8-K, 2026-10-05
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-08-11
- · In / out: In · Person: Carolyn S. Starrett · Role: Director · 8-K, 2026-06-25
Neogenomics Inc reported changes in 3 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-06-25 to 2026-10-05. They name 2 people, with 1 appointment and 1 departure. Every row below is cited to the filing it comes from, and this page adds each new change as Neogenomics Inc files it.
Also on the record for Neogenomics Inc
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 14, 2026 | Stake report, Schedule 13G/A, by Mathew P. Arens | 8.37% of the class | 5%+ stakes | Source |
| July 30, 2026 | Stake report, Schedule 13G, by First Trust Portfolios L.P. | 7.77% of the class | 5%+ stakes | Source |
| July 30, 2026 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 15.6% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by Greenhouse Funds LLLP | 7.1% of the class | 5%+ stakes | Source |
| May 13, 2026 | Stake report, Schedule 13G/A, by Millennium Management LLC | 1.7% of the class | 5%+ stakes | Source |
| May 7, 2026 | Stake report, Schedule 13G/A, by Mathew P. Arens | 10.82% of the class | 5%+ stakes | Source |
| April 30, 2026 | Stake report, Schedule 13G, by Vanguard Capital Management | 5.09% of the class | 5%+ stakes | Source |
| April 29, 2026 | Stake report, Schedule 13G, by Vanguard Portfolio Management | 5.91% of the class | 5%+ stakes | Source |
| March 27, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| December 9, 2025 | Stake report, Schedule 13G, by Millennium Management LLC | 5% of the class | 5%+ stakes | Source |
| December 2, 2025 | Stake report, Schedule 13G, by Millennium Management LLC | 4.97% of the class | 5%+ stakes | Source |
| October 17, 2025 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 14.6% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Neogenomics Inc now and the warning signs.
Free to see. No signup.
Keep reading
More on Neogenomics Inc and the records around it.
Neogenomics Inc elsewhere on the record
- 5%+ stake filings Aug 2026
- Who owns it
Companies that share a holder
- Greenhouse Funds LLLP also filed stake reports on 5 other companies: NCR Voyix Corp (Sep 2026), Clarus Corporation (May 2026), PHREESIA, INC. (Feb 2026)
- First Light Asset Management, LLC also filed stake reports on 12 other companies: NeuroPace Inc (Sep 2026), PALVELLA THERAPEUTICS, INC. (Aug 2026), TriSalus Life Sciences, Inc. (Jul 2026)
- Integrated Core Strategies (US) LLC also filed stake reports on 63 other companies: SkinHealth Systems Inc. (Nov 2026), Infinite Eagle Acquisition Corp. (Nov 2026), Longeveron Inc. (Nov 2026)
Watch Neogenomics Inc
Get an email when Neogenomics Inc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Neogenomics Inc?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Neogenomics Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Neogenomics Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
15 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 15 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-10-05 | Out | Chair of the Board | 2027-01-04 | 8-K, 2026-10-05 | |
| 2026-08-11 | Reported | not named in the filing | 8-K, 2026-08-11 | ||
| 2026-06-25 | In | Director | 8-K, 2026-06-25 |
Who leads Neogenomics Inc, as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chair of the Board: Lynn Tetrault, departure reported, effective 2027-01-04 (filed 2026-10-05). No successor is named in these filings.
- Director: Carolyn S. Starrett, appointed (filed 2026-06-25).
New leaders reset buying decisions — get the Full Report on Neogenomics Inc: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chair of the Board at Neogenomics Inc, with the record behind each one.
Find candidates like Chair of the Board at Neogenomics IncEvery change, in the filing's words
Departing: Lynn Tetrault, Chair of the Board, effective 2027-01-04
Board Changes In connection with the executive transitions described above, Lynn Tetrault, the current Chair of the Board, will step down as Chair, effective as of January 4, 2027.
- Departure of Directors of Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
- CEO Transition On September 30, 2026, the Board of Directors (the "Board") of the Company approved the appointment of Warren Stone, the Company's current President and Chief Operating Officer, as Chief Executive Officer of the Company and a member of the Board, effective as of January 4, 2027.
- In connection with Mr. Stone's appointment as Chief Executive Officer, on September 30, 2026, the Board also approved the executive transition of Tony Zook, the Company's current Chief Executive Officer and a member of the Board, to the role of Executive Chairman, effective as of January 4, 2027.
- Mr. Stone, 54, joined the Company in November 2022 as the Company's President, Clinical Services, was appointed as Chief Commercial Officer in April 2024 and was appointed President & Chief Operating Officer in April 2025.
- Prior to joining the Company, from 2020 to 2022, Mr. Stone was President, Commercial Americas for Ortho Clinical Diagnostics, a leading global provider of in-vitro diagnostics solutions to the clinical laboratory and transfusion medicine communities.
Reported
On August 11, 2026, NeoGenomics, Inc. (the "Company") announced that Alicia Olivo, EVP, General Counsel & Business Development, would transition from her role with the Company and cease to serve as General Counsel effective as of September 21, 2026.
- Ms. Olivo will remain an employee of the Company until October 2, 2026 for transitional purposes.
Appointed: Carolyn S. Starrett, Director
On June 23, 2026, the Board of Directors (the "Board") of NeoGenomics, Inc. (the "Company") increased the size of the Board from nine to ten directors and appointed Carolyn S. Starrett as a director to fill the newly created vacancy, effective immediately.
- Ms. Starrett will serve as a member of the Board until the 2027 annual meeting of stockholders of the Company and until her successor is duly elected and qualified (or, if earlier, her resignation or removal).
- Ms. Starrett will receive compensation for her service as an independent director consistent with the Company's director compensation program as previously disclosed in the Company's definitive proxy statement for its 2026 annual meeting of stockholders.
Tools for this story
Each opens in a new tab, filled in for Neogenomics Inc. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.